Why 3 g Is Better Than 1.5 g?
This video describes about the comparison between MAGNEX® (cefoperazone/sulbactam) doses: Why MAGNEX® 3.0 g (vials of the 1:2 product containing the equivalent of 1000 mg + 2000 mg of sulbactam and cefoperazone) is better than MAGNEX® 1.5 g (vials of the 1:2 product containing the equivalent of 500 mg + 1000 mg of sulbactam and cefoperazone)?
PP-MGX-IND-0457
Efficacy of BL/BLIs Versus Carbapenems
This video describes similar efficacy between BL/BLI combinations and carbapenems in patients with sepsis.
PP-MGX-IND-0463
Relatively Lower Emergence of Resistance Against Microorganisms in Comparison With Other Antibiotics
This video describes MAGNEX®’s relatively lower emergence of resistance against microorganisms. Cefoperazone/Sulbactam is one of the antimicrobials that showed the least resistance to ESBL-producing organisms – evidence from an Indian setting.
PP-MGX-IND-0462
MAGNEX® in the Treatment of Pneumonia
This video provides information about MAGNEX® in the treatment of pneumonia (HAP, VAP). Nosocomial pneumonia showed high incidence and mortality in the Indian population. The ICMR guidelines recommend cefoperazone/sulbactam for culture-proven VAP/HAP.
PP-MGX-IND-0461
MAGNEX® in the Treatment of FN
This video provides information about the management of FN and the effectiveness of MAGNEX® in the treatment of FN. MAGNEX® exhibited a treatment success rate similar to those of comparator drugs for the treatment of FN.
PP-MGX-IND-0460
Management of IAIs With MAGNEX®
This video provides information on the treatment of IAIs with MAGNEX®. The ICMR guidelines recommend the management of IAIs with cefoperazone/sulbactam.
PP-MGX-IND-0459
This video provides information on the treatment of UTIs with MAGNEX® (cefoperazone/sulbactam).
PP-MGX-IND-0458
Reference:
1. Magnex. Local product document. Pfizer; 2020. Version LPDMGX042020.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.